Childhood asthma: breakthroughs and challenges (Q36647136)

15 August 2017

1 reference

title

Childhood asthma: breakthroughs and challenges (English)

1 reference

15 August 2017

1 reference

Henry Milgrom

1

1 reference

15 August 2017

publication date

1 January 2006

1 reference

15 August 2017

published in

Advances in pediatrics

1 reference

15 August 2017

volume

53

1 reference

15 August 2017

page(s)

55-100

1 reference

Prevalence, impact, and trends in childhood disability due to asthma

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Keeping children out of hospitals: parents' and physicians' perspectives on how pediatric hospitalizations for ambulatory care-sensitive conditions can be avoided

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Trends in childhood asthma: prevalence, health care utilization, and mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Continuing decreases in asthma mortality in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Improved asthma care after enrollment in the State Children's Health Insurance Program in New York

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Poverty, race, and medication use are correlates of asthma hospitalization rates. A small area analysis in Boston

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Variations in asthma hospitalizations and deaths in New York City

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Asthma hospitalization rates and socioeconomic status in New York State (1987-1993)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Characteristics of inner-city children with asthma: the National Cooperative Inner-City Asthma Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Health consequences associated with frequent wheezing in adolescents without asthma diagnosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Racial and ethnic differences in asthma diagnosis among children who wheeze

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Asthma and wheezing in the first six years of life. The Group Health Medical Associates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Tucson Children's Respiratory Study: 1980 to present

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

The Copenhagen Prospective Study on Asthma in Childhood (COPSAC): design, rationale, and baseline data from a longitudinal birth cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Viral infections, cytokine dysregulation and the origins of childhood asthma and allergic diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Outcome of asthma and wheezing in the first 6 years of life: follow-up through adolescence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Early respiratory infections, asthma, and allergy: 10-year follow-up of the Oslo Birth Cohort

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

A longitudinal, population-based, cohort study of childhood asthma followed to adulthood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

The incidence of asthma in young adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Remodeling in asthma and chronic obstructive lung disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Airway remodeling: therapeutic target or not?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Markers of eosinophilic inflammation and tissue re-modelling in children before clinically diagnosed bronchial asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Changing prevalence of allergic rhinitis and asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Environment and development of atopy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Declining asthma prevalence in Hong Kong Chinese schoolchildren.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Prevalence of asthma and allergy in schoolchildren in Belmont, Australia: three cross sectional surveys over 20 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

No increase in the prevalence of asthma, allergies, and atopic sensitisation among children in Germany: 1992-2001.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Total serum IgE and its association with asthma symptoms and allergic sensitization among children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Atopic characteristics of children with recurrent wheezing at high risk for the development of childhood asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

The role of allergy in the development of asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Targeting the IgE molecule in allergic and asthmatic diseases: review of the IgE molecule and clinical efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Mast-cell infiltration of airway smooth muscle in asthma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

An optimal bronchial tree may be dangerous

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Self-organized patchiness in asthma as a prelude to catastrophic shifts.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Management of the Acute Exacerbation of Asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

7 January 2021

Brave new allergic world

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Advances in childhood asthma: hygiene hypothesis, natural history, and management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Relation between house-dust endotoxin exposure, type 1 T-cell development, and allergen sensitisation in infants at high risk of asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Siblings, day-care attendance, and the risk of asthma and wheezing during childhood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

A longitudinal analysis of wheezing in young children: the independent effects of early life exposure to house dust endotoxin, allergens, and pets.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Endotoxin exposure and eczema in the first year of life

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Exposure to farming in early life and development of asthma and allergy: a cross-sectional survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

The Canadian asthma primary prevention study: outcomes at 2 years of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Mucosal immunity and allergic responses: lack of regulation and/or lack of microbial stimulation?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Air pollution and allergy: you are what you breathe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Low-grade systemic inflammation in overweight children

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

inferred from DOI database lookup

7 January 2021

based on heuristic

Obesity: insight into the origins of asthma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Persistence of asthma symptoms during adolescence: role of obesity and age at the onset of puberty

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Is the hygiene hypothesis still a viable explanation for the increased prevalence of asthma?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Proinflammatory cytokines and leptin are increased in serum of prepubertal obese children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Evidence of a role of tumor necrosis factor alpha in refractory asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Inhibition of tumor necrosis factor alpha for refractory asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Effect of tumor necrosis factor antagonism on allergen-mediated asthmatic airway inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Asthma and gastroesophageal reflux disease in children: exploring the relationship

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Effects of viral respiratory infections on lung development and childhood asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Rhinovirus illnesses during infancy predict subsequent childhood wheezing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Rhinovirus and respiratory syncytial virus in wheezing children requiring emergency care. IgE and eosinophil analyses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Eosinophil cationic protein in serum and nasal washes from wheezing infants and children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

The relationship between upper respiratory infections and hospital admissions for asthma: a time-trend analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Human metapneumovirus infection in children hospitalized for wheezing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Viral infections in relation to age, atopy, and season of admission among children hospitalized for wheezing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Present and future treatment of asthma in infants and young children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Heterogeneity of the association between lower respiratory illness in infancy and subsequent asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Linkage between immunoglobulin E responses underlying asthma and rhinitis and chromosome 11q

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Perspectives on the past decade of asthma genetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Asthma genetics 2006: the long and winding road to gene discovery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

The immunogenetics of asthma and eczema: a new focus on the epithelium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Genetic Susceptibility to Asthma — Bronchial Hyperresponsiveness Coinherited with a Major Gene for Atopy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Epidemiology of acute asthma: IgE antibodies to common inhalant allergens as a risk factor for emergency room visits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Toll-like receptors in the pathogenesis of human disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Toll-like receptor 2 as a major gene for asthma in children of European farmers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

TOLL-like receptor 10 genetic variation is associated with asthma in two independent samples

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Association of the interleukin-1 receptor antagonist gene with asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Transforming growth factor-beta1 promoter polymorphism C-509T is associated with asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Polymorphisms in a disintegrin and metalloprotease 33 (ADAM33) predict impaired early-life lung function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Association of a disintegrin and metalloprotease 33 (ADAM33) gene with asthma in ethnically diverse populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Asthma is associated with single-nucleotide polymorphisms in ADAM33.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Recent developments in asthma management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

ADAM33 is not associated with asthma in Puerto Rican or Mexican populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

ADAM33 polymorphisms and phenotype associations in childhood asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

ADAM33: where are we now?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Airway smooth muscle in asthma--not just more of the same

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Airway smooth muscle cell proliferation is increased in asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Dysfunctional interaction of C/EBPalpha and the glucocorticoid receptor in asthmatic bronchial smooth-muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Asthma phenotypes in childhood: lessons from an epidemiological approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Airway remodeling and inflammation in symptomatic infants with reversible airflow obstruction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Epithelial stress and structural remodelling in childhood asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Persistent wheezing in very young children is associated with lower respiratory inflammation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Long-term effects of budesonide or nedocromil in children with asthma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Progression of asthma measured by lung function in the childhood asthma management program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Relation of beta2-adrenoceptor polymorphisms at codons 16 and 27 to persistence of asthma symptoms after the onset of puberty

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Predicting adult asthma in childhood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Longitudinal follow-up of the changing gender ratio in asthma from childhood to adulthood: role of delayed manifestation in girls

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Adult asthma severity in individuals with a history of childhood asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

The Melbourne Asthma Study: 1964-1999.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Association between allergy and asthma from childhood to middle adulthood in an Australian cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Asthma in remission: can relapse in early adulthood be predicted at 18 years of age?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Factors associated with persistent airflow limitation in severe asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Risk factors for airway remodeling in asthma manifested by a low postbronchodilator FEV1/vital capacity ratio: a longitudinal population study from childhood to adulthood.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Bronchial hyperresponsiveness in adolescents with long-term asthma remission: importance of a Family history of bronchial hyperresponsiveness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Keeping children with exercise-induced asthma active

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Asthma and activities of daily living

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Minimum skills required by children to complete health-related quality of life instruments for asthma: comparison of measurement properties.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

7 January 2021

Vocal cord dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Asthma therapy for children under 5 years of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Is forced expiratory volume in one second the best measure of severity in childhood asthma?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Prevalence and impact of multiple childhood chronic illnesses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Rhinosinusitis: establishing definitions for clinical research and patient care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Treatment of eosinophilic esophagitis with specific food elimination diet directed by a combination of skin prick and patch tests.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Eosinophilic esophagitis: a 10-year experience in 381 children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Clinical characteristics of eosinophilic esophagitis in children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. On behalf of the Italian Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

A comparison of inhaled fluticasone and oral prednisone for children with severe acute asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Asthma deaths during sports: report of a 7-year experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Long-term safety of fluticasone propionate and nedocromil sodium on bone in children with asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Early treatment of asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Decrease in hospitalization for treatment of childhood asthma with increased use of antiinflammatory treatment, despite an increase in prevalence of asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Daily versus as-needed corticosteroids for mild persistent asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Pediatric asthma: an approach to pharmacogenetics analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Fluticasone improves pulmonary function in children under 2 years old with risk factors for asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Twelve-month safety and efficacy of inhaled fluticasone propionate in children aged 1 to 3 years with recurrent wheezing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

The effect of inhaled budesonide on symptoms, lung function, and cold air and methacholine responsiveness in 2- to 5-year-old asthmatic children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

The Effect of Inhaled Fluticasone Propionate in the Treatment of Young Asthmatic Children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Prednisolone treatment of respiratory syncytial virus infection: a randomized controlled trial of 147 infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Respiratory syncytial virus bronchiolitis: a double-blind dexamethasone efficacy study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Randomised controlled trial of budesonide for the prevention of post-bronchiolitis wheezing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

No objective benefit from steroids inhaled via a spacer in infants recovering from bronchiolitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

A comparison between nebulized terbutaline, nebulized corticosteroid and systemic corticosteroid for acute wheezing in children up to 18 months of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Randomised double blind placebo controlled trial of prednisolone in children admitted to hospital with respiratory syncytial virus bronchiolitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Inhaled steroids for episodic viral wheeze of childhood

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Systemic effects of inhaled corticosteroids in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Effect of long-term treatment with inhaled budesonide on adult height in children with asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Double-blind trial of steroid tapering in acute asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

"Black box" 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Is there a problem with inhaled long-acting beta-adrenergic agonists?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Bronchodilator treatment and deaths from asthma: case-control study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Safety of long-acting beta-agonists--an urgent need to clear the air.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Long-acting β2 agonists and paediatric asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Significant variability in response to inhaled corticosteroids for persistent asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. The Dutch Asthma Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Exhaled nitric oxide before and after montelukast sodium therapy in school-age children with chronic asthma: A preliminary study

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

inferred from DOI database lookup

7 January 2021

based on heuristic

Effect of montelukast added to inhaled corticosteroids on fractional exhaled nitric oxide in asthmatic children

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Characterization of within-subject responses to fluticasone and montelukast in childhood asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Modulation of agonist-induced phosphoinositide metabolism, Ca2+ signalling and contraction of airway smooth muscle by cyclic AMP-dependent mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Beta2-agonist tolerance and exercise-induced bronchospasm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Bronchodilator tolerance: the impact of increasing bronchoconstriction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Comparison of R-, S-, and RS-albuterol interaction with human beta 1- and beta 2-adrenergic receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Effect of single doses of S-salbutamol, R-salbutamol, racemic salbutamol, and placebo on the airway response to methacholine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Salbutamol enantiomers: early clinical evidence in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Levalbuterol: pharmacologic properties and use in the treatment of pediatric and adult asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Low-dose levalbuterol in children with asthma: safety and efficacy in comparison with placebo and racemic albuterol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Single-isomer levalbuterol: a review of the acute data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Effect of nebulized ipratropium on the hospitalization rates of children with asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Efficacy of ipratropium bromide in acute childhood asthma: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Acute asthma in children and adolescents: should inhaled anticholinergics be added to beta(2)-agonists?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Regional variation in ICU care for pediatric patients with asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Anticholinergic drugs for wheeze in children under the age of two years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Inhaled disodium cromoglycate (DSCG) as maintenance therapy in children with asthma: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Growth, systemic safety, and efficacy during 1 year of asthma treatment with different beclomethasone dipropionate formulations: an open-label, randomized comparison of extrafine and conventional aerosols in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Outpatient management practices associated with reduced risk of pediatric asthma hospitalization and emergency department visits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

A randomized trial comparing peak expiratory flow and symptom self-management plans for patients with asthma attending a primary care clinic.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

IgE inhibition as a therapy for allergic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Effect of anti-IgE therapy in patients with peanut allergy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

PROPHYLACTIC INOCULATION AGAINST HAY FEVER

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Status of immunotherapy: current and future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

IL-13 production by allergen-stimulated T cells is increased in allergic disease and associated with IL-5 but not IFN-gamma expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Immunotherapy: 1999-2004.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Evaluation of near-fatal reactions to allergen immunotherapy injections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Safety of infliximab treatment in pediatric patients with inflammatory bowel disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: a population-based cross-sectional study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Mite (Der p 1, Der f 1) and cat (Fel d 1) allergens in the homes of babies with a family history of allergy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Clothing is a carrier of cat allergens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Control of Exposure to Mite Allergen and Allergen-Impermeable Bed Covers for Adults with Asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Results of a home-based environmental intervention among urban children with asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Fish oil supplementation reduces severity of exercise-induced bronchoconstriction in elite athletes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Physical activity in urban school-aged children with asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Regular inhaled beta agonist in asthma: effects on exacerbations and lung function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Polymorphisms of the beta2-adrenergic receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Genetics and the variability of treatment response in asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Steroid-unresponsive asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

CD56+ cells induce steroid resistance in B cells exposed to IL-15.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Characterization of the human 5-lipoxygenase gene promoter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Influence of leukotriene pathway polymorphisms on response to montelukast in asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

The utility of peak flow, symptom scores, and beta-agonist use as outcome measures in asthma clinical research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Risk of severe asthma episodes predicted from fluctuation analysis of airway function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Nitric oxide as a clinical guide for asthma management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Use of exhaled nitric oxide measurements to guide treatment in chronic asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Relationship of exhaled nitric oxide to clinical and inflammatory markers of persistent asthma in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Heterogeneity of FeNO response to inhaled steroid in asthmatic children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Nitric oxide in chronic airway inflammation in children: diagnostic use and pathophysiological significance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

NO in Exhaled Air of Asthmatic Children Is Reduced by the Leukotriene Receptor Antagonist Montelukast

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Clinical use of noninvasive measurements of airway inflammation in steroid reduction in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Leukotrienes and 8-isoprostane in exhaled breath condensate of children with stable and unstable asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Increased exhaled 8-isoprostane in childhood asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Gas chromatography/mass spectrometry analysis of exhaled leukotrienes in asthmatic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Short-term compliance with peak flow monitoring: results from a study of inner city children with asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Noncompliance and treatment failure in children with asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Patient compliance in a clinical trial with inhaled budesonide in children with mild asthma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

The odds of the three nons when an aptly prescribed medicine isn't working: non-compliance, non-absorption, non-response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Filling the gap between knowing and doing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Treatment patterns in the months prior to and after asthma-related emergency department visit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Use of asthma guidelines by primary care providers to reduce hospitalizations and emergency department visits in poor, minority, urban children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Management of chronic disease by practitioners and patients: are we teaching the wrong things?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Applying epidemiologic concepts of primary, secondary, and tertiary prevention to the elimination of racial disparities in asthma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YAPD.2006.04.007

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YAPD.2006.04.007

1 reference

15 August 2017

1 reference